FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis

BACKGROUND: Doublets plus anti‐epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI‐bevacizumab is superior to doublets plus bevacizumab independently from primar...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Pietrantonio, Filippo, Fucà, Giovanni, Rossini, Daniele, Schmoll, Hans‐Joachim, Bendell, Johanna C., Morano, Federica, Antoniotti, Carlotta, Corallo, Salvatore, Borelli, Beatrice, Raimondi, Alessandra, Marmorino, Federica, Niger, Monica, Boccaccino, Alessandra, Masi, Gianluca, Lonardi, Sara, Boni, Luca, de Braud, Filippo, Di Bartolomeo, Maria, Falcone, Alfredo, Cremolini, Chiara
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2021
Assuntos:
Gastrointestinal Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018298/
https://ncbi.nlm.nih.gov/pubmed/33336844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13642
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados